The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
Open Access
- 1 August 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 1909-1918
Abstract
Introduction: Early identification of preventable risk factors of COPD progression is important. Whether exacerbations have a negative impact on disease progression is largely unknown. We investigated whether the long-term occurrence of exacerbations is associated with lung function decline at early stages of COPD. Methods: Patients diagnosed with mild/moderate COPD (obstruction and FEV1% predicted 50– 90%), aged ≥ 35 years, and a smoking history, who had ≥ 6 years of UK electronic medical records after initiation of maintenance therapy were studied. Multilevel mixed-effect linear regression was performed to determine the association between the count of any year in which the patient had ≥ 1 exacerbation over a 6-year period and FEV1 decline, adjusted for sex, age, anthropometrics and smoking habits. Exacerbations were defined as any prescription for an acute oral corticosteroid course and/or lower respiratory-related antibiotics and/or any COPD-related emergency or inpatient hospitalization. Results: Of 11,337 patients included (mean age 65 years; 49% female) 31.6%, 23.3%, 16.6%, 11.6%, 8.1%, 5.3% and 3.4% had 0, 1, 2, 3, 4, 5 and 6 years with ≥ 1 exacerbation. The mean annual FEV1 decline accelerated by 1.50 mL/year (95% Confidence Interval 1.02; 1.98) with every additional year with ≥ 1 exacerbation from 31.0 mL/year in subjects without any exacerbation to 40.0 mL/year in patients experiencing ≥ 1 exacerbation every year. Patients with more years with ≥ 1 exacerbation had a lower mean FEV1 at first diagnosis: 14.7 mL (11.7; 17.8) lower with every additional year with exacerbations. When counting years with ≥ 2 exacerbations, greater effects were observed (2.19 [1.50; 2.88] mL/year excess decline per year with ≥ 2 exacerbations; 16.5 mL [12.1; 20.8] lower FEV1 at diagnosis). Conclusion: Patients who experienced a greater exacerbation burden after initiation of maintenance therapy had worse lung function at diagnosis and a more rapid lung function decline thereafter, which emphasizes the need for better treatment strategies.Keywords
This publication has 20 references indexed in Scilit:
- Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspectiveRespiratory Research, 2019
- Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapyRespiratory Research, 2016
- Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)BMJ Open, 2014
- Strategies for Handling Missing Data in Electronic Health Record Derived DataeGEMs (Generating Evidence & Methods to improve patient outcomes), 2013
- Population-Based Burden of COPD-Related Visits in the EDChest, 2013
- Exacerbation frequency and course of COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH StudyAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Exacerbations and lung function decline in COPD: New insights in current and ex-smokersRespiratory Medicine, 2007
- How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respiratory Medicine, 2005